Lineage Cell Therapeutics (LCTX) Cash & Equivalents Growth (5y) (2015 - 2026)

Lineage Cell Therapeutics (LCTX) Cash & Equivalents Growth (5y) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Lineage Cell Therapeutics 251.15 Mn 188.44 Mn 1.73 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -4.23%
Dec 31, 2025 7.12%
Sep 30, 2025 -0.21%
Jun 30, 2025 27.24%
Mar 31, 2025 37.25%
Dec 31, 2024 33.99%
Sep 30, 2024 14.07%
Jun 30, 2024 29.26%
Mar 31, 2024 19.33%
Dec 31, 2023 4.88%
Sep 30, 2023 10.09%
Jun 30, 2023 4.49%
Mar 31, 2023 -12.33%
Dec 31, 2022 -20.97%
Sep 30, 2022 8.24%
Jun 30, 2022 37.25%
Mar 31, 2022 25.92%
Dec 31, 2021 20.34%
Sep 30, 2021 14.83%
Jun 30, 2021 17.48%